Stay updated on Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial

Sign up to get notified when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    4%
    Check dated 2025-07-11T06:55:12.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    5%
    Check dated 2025-07-04T01:06:17.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    4%
    Check dated 2025-06-19T17:27:29.000Z thumbnail image
  5. Check
    32 days ago
    No Change Detected
  6. Check
    39 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.3%
    Check dated 2025-06-05T07:56:35.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    6%
    Check dated 2025-05-29T05:36:29.000Z thumbnail image
  8. Check
    53 days ago
    Change Detected
    Summary
    The trial of pre-operative Neratinib and endocrine therapy with Trastuzumab in ER-positive, HER-2 positive breast cancers has been removed from the page.
    Difference
    0.3%
    Check dated 2025-05-22T01:39:54.000Z thumbnail image

Stay in the know with updates to Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.